Analyst Coverage
| Analyst | Firm |
|---|---|
| Sean Wu | Morgan Stanley |
| Chen Chen | UBS |
| Roanna Ruiz | SVB Securities |
| Ziyu He, Yizheng Yang | CICC |
| Haichun Zhao | Sinolink Securities |
| Xiaowei Lin | Everbright Securities |
- Home
-
Company
-
Science
-
Media
- Back
-
Press Release
- Back
- Brii Biosciences Announces Upcoming Conference Participation in November
- Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
- Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
- Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
- Brii Biosciences Announces China Leadership Team Changes
- Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
- Brii Biosciences Announces Upcoming Conference Participation in September
- Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
- WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
- Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
- FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
- Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
- VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
- Brii Biosciences Expands Infectious Disease Pipeline
- Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
- Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
- Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
- Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
- Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
- Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
- Brii Biosciences Closes US$155 Million Series C Financing
- Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
- Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
- Brii Biosciences Provides Update on Strategic Clinical Development Progress
- Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
- Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
- Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
- Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
- Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
- Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
- Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
- Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
- Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
- Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
- Brii Biosciences Announces Upcoming Participation at November Conferences
- Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
- Brii Biosciences Joins Hang Seng Composite Index
- Brii Biosciences Included in Hong Kong Stock Connect
- Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
- Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
- Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
- Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
- Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
- Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
- Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
- Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
- Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
- Brii Biosciences Announces Upcoming Conference Participation in July
- Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
- Brii Biosciences Announces Upcoming Conference Participation in June
- Brii Biosciences to be Added to MSCI China Small Cap Index
- Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
- Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
- Brii Biosciences Announces Upcoming Participation at May Conference
- Brii Biosciences Announces Upcoming Participation at April Conferences
- Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
- Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
- Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
- Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
- Brii Biosciences Announces Upcoming Participation at March Conferences
- Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
- Brii Biosciences Announces Upcoming Conference Participation in January
- Brii Biosciences Provides Update on Strategic Clinical Development Progress
- Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
-
Media Reports
-
Investor Relations
- Careers
- Contact Us
- Home
-
Company
-
Science
-
Media
- Back
-
Press Release
- Back
- Brii Biosciences Announces Upcoming Conference Participation in November
- Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
- Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
- Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
- Brii Biosciences Announces China Leadership Team Changes
- Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
- Brii Biosciences Announces Upcoming Conference Participation in September
- Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
- WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
- Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
- FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
- Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
- VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
- Brii Biosciences Expands Infectious Disease Pipeline
- Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
- Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
- Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
- Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
- Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
- Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
- Brii Biosciences Closes US$155 Million Series C Financing
- Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
- Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
- Brii Biosciences Provides Update on Strategic Clinical Development Progress
- Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
- Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
- Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
- Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
- Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
- Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
- Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
- Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
- Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
- Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
- Brii Biosciences Announces Upcoming Participation at November Conferences
- Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
- Brii Biosciences Joins Hang Seng Composite Index
- Brii Biosciences Included in Hong Kong Stock Connect
- Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
- Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
- Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
- Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
- Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
- Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
- Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
- Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
- Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
- Brii Biosciences Announces Upcoming Conference Participation in July
- Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
- Brii Biosciences Announces Upcoming Conference Participation in June
- Brii Biosciences to be Added to MSCI China Small Cap Index
- Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
- Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
- Brii Biosciences Announces Upcoming Participation at May Conference
- Brii Biosciences Announces Upcoming Participation at April Conferences
- Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
- Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
- Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
- Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
- Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
- Brii Biosciences Announces Upcoming Participation at March Conferences
- Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
- Brii Biosciences Announces Upcoming Conference Participation in January
- Brii Biosciences Provides Update on Strategic Clinical Development Progress
- Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
-
Media Reports
-
Investor Relations
- Careers
- Contact Us